What kinds of cancer can ZIRABEV help to treat?

INDICATIONS

Metastatic Colorectal Cancer

ZIRABEV is approved to treat metastatic colorectal cancer (mCRC) for:

  • First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
  • Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes a bevacizumab product

ZIRABEV is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Non–Small Cell Lung Cancer

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non–squamous non–small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma

ZIRABEV is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

Metastatic Renal Cell Carcinoma

ZIRABEV, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

Persistent, Recurrent, or Metastatic Cervical Cancer

ZIRABEV, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.